AZ’s Fasenra set to revolutionise COPD treatment as Phase III data builds anticipation

AstraZeneca’s Fasenra, a monoclonal antibody targeting eosinophilic inflammation, is set to revolutionize COPD treatment with its highly anticipated Phase III data to be presented at the 2025 J.P. Morgan Healthcare Conference. With the success of biologic Dupixent paving the way for a new treatment paradigm, Fasenra’s ability to reduce eosinophilic inflammation.